Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 10/20 | 1.00 |
| ▸ | EGLN2 | Q96KS0 | 10/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563833 | 0.93 | P4HTM (1.00) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL565178 | 0.90 | P4HTM (0.90) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL4752070 | 0.86 | P4HTM (0.82) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| Hydrochloric Acid SCHEMBL2567646 | 0.85 | P4HTM (0.81) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL4752265 | 0.84 | P4HTM (0.93) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL1362381 | 0.83 | P4HTM (1.00) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL563842 | 0.81 | P4HTM (1.00) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| Trifluoroacetic Acid SCHEMBL2571256 | 0.80 | P4HTM (0.80) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL564938 | 0.79 | EGLN2 (0.70) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL565165 | 0.76 | P4HTM (0.86) | P4HTMEGLN2EGLN1EGLN3HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265602-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER IP GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| EP-2265602-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER IP GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| CN-102015685-B | Substituted dihydropyrazolones as HIF-prolyl-4-hydroxylase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-15 | — | — | CN | disclosed |
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067407-B2 | Substituted dihydropyrazolones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-29 | — | — | US | disclosed |
| CN-102015685-A | Substituted dihydropyrazolones as HIF-prolyl-4-hydroxylase inhibitors | BAYER SCHERING PHARMA AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2265602-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009129945-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129945-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038938-A1 | Substituted dihydropyrazolones and their use | GLS, ATP6V1B1, PFKP | P4HTM 685/4885EGLN2 301/4885EGLN1 1427/4885 |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | P4HTM 685/4885EGLN2 301/4885EGLN1 1427/4885 |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | P4HTM 685/4885EGLN2 301/4885EGLN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.